Key statistics about Coronary Artery Disease (CAD)
• In about 50% of cases, a heart attack is the first sign of CAD.
• More than 1 million diagnostic catheterizations are performed annually in the U.S., costing $16 B/yr.
• At least 40% of catheterizations return a “normal” result, and thus, are unnecessary.
• About 9 million myocardial imaging tests are performed each year in the U.S. at a cost of > $1 billion.
• Roughly 60-70% of imaging tests return a normal result, thus, are also unnecessary.
• TruCAD development in 100 patients indicates 80% accuracy versus clinical standard of 54%.
Economics of TruCAD
• Total addressable market is approximately 10 million U.S. adults presenting with symptoms of CAD.
• Potential expansion into “at risk” adult health testing market is 8-10 times greater.
• The market will expand by multiples with worldwide use, especially in countries with limited access to sophisticated cardiac imaging systems.
• Unlike existing invasive or non-invasive cardiac imaging systems, TruCAD could be employed multiple times over the course of a patient’s treatment to monitor the disease process, and tailor various therapies.